GSK Q2 Sales Rise 7% to £8.4 Billion, Reaffirms 2026 Growth Forecast
2026-07-28 12:22:34
GlaxoSmithKline reported second-quarter total sales of £8.4 billion, up 7% year on year, with specialty medicines sales rising 14% to £3.8 billion and vaccines sales up 8% to £2.3 billion, while general medicines sales fell 9% to £2.3 billion, according to Jiemian News. Core operating profit for the quarter was £2.8 billion and core earnings per share were 50.5 pence. The company said it expects 2026 full-year sales to grow 3% to 5%, core operating profit to rise 7% to 9%, and core EPS to increase 7% to 9%.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
PayPal 在第二季度策略中强调稳定币与 AI 驱动支付工具
